Drug Profile
Calcitonin intranasal - Neurelis
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Aegis Therapeutics
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones; Small molecules
- Mechanism of Action Calcitonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer pain
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Cancer-pain in USA (Intranasal)